sacituzumab govitecan

medtigo

sacituzumab govitecan

Brand Name :

sacituzumab govitecan-hziy, Trodelvy

Synonyms :

sacituzumab govitecan

Class :

Antineoplastic Agent, Topoisomerase Inhibitors

Action and Spectrum

Actions and Spectrum:

sacituzumab govitecan is a drug used to treat certain types of cancer, including triple-negative breast cancer and non-small cell lung cancer.

Dosing & Uses

Drug Interaction

Adverse Reaction

>10%:

Decreased hemoglobin (93%)

Decreased neutrophils (82%)

Decreased leukocytes (91%)

Nausea (69%)

Diarrhea (63%)

Increased glucose (48%)

Increased AST (45%)

Alopecia (38%)

Increased ALT (35%

Decreased sodium (25%)

Increased magnesium (24%)

Back pain (23%)

Dyspnea (21%)

Hypomagnesemia (21%)

Pruritus (17%)

Arthralgia (17%)

Thrombocytopenia (14%)

Insomnia (13%)

1-10%:

Hypophosphatemia (9%)

Vomiting (6%)

Decreased hemoglobin (6%)

Rash (3%)

Urinary tract infection (3%)

Decreased calcium (3%)

Increased glucose (3%)

Constipation (1%)

Abdominal pain (1%)

Hypomagnesemia (1%)

Black Box Warning

Black Box Warning:

It is essential to follow the dosage and administration instructions for the medication carefully.

Monitor diarrheal patients.

Provide electrolytes to them.

Withhold the therapy if severe diarrhea persists.

Contraindication / Caution

Contraindication/Caution:

sacituzumab govitecan should not be used in people hypersensitive to the drug itself.

Pregnancy / Lactation

Pregnancy consideration:

No data is available regarding the drug-associated effects during pregnancy.

But the mechanism of action defines the teratogenic effect on the fetus.

Breastfeeding warnings:

No data is available regarding the presence of the drug in human breast milk.

Pregnancy category:

Category A: well-controlled and Satisfactory studies do not show risk to the fetus in the first/later trimester.       
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.       
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.      
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.       
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.       
Category N: No data is available for the drug under this category.

Pharmacology

Pharmacology

sacituzumab govitecan is an antibody-drug conjugate (ADC) that targets the protein Trop-2, found on many cancer cells’ surfaces. The drug comprises a monoclonal antibody, sacituzumab, that binds specifically to Trop-2, and a chemotherapy drug, SN-38, linked to the antibody.

Pharmacodynamics:

When sacituzumab govitecan binds to the Trop-2 protein on the cancer cell, the chemotherapy drug is internalized into the cell, where it is activated. It begins to inhibit the cancer cell’s growth and replication.

SN-38 is a topoisomerase 1 inhibitor; it can inhibit DNA replication by binding to topoisomerase 1. It stabilizes the covalent complex between the enzyme and the DNA. It further leads to DNA damage and apoptosis of the cancer cells.

Pharmacokinetics:

The pharmacokinetics of sacituzumab govitecan still needs to be well established. Still, it has been observed that the drug has a moderate to long half-life in the body, and patients tolerate it well.

Absorption

The peak plasma concentration is 243,000 ng/mL

The area under the curve value is 5,210,000 ng⋅hr/mL

Distribution

After IV administration, sacituzumab govitecan is distributed to other organs. Its volume of distribution is about 0.045 L/kg

Metabolism

The monoclonal antibody component of the drug, sacituzumab, is thought to be metabolized by the same pathways as other antibodies, which involve proteolytic degradation and excretion in the urine.

The liver metabolizes the chemotherapy drug component, SN-38, into its active SN-38 glucuronide. It is excreted primarily in the urine. SN-38 glucuronide has been shown to have similar activity as SN-38 and is responsible for the drug’s anti-tumor effect.

Elimination and excretion

sacituzumab govitecan has a plasma half-life of about 18 hours. The total body clearance of the drug is 0.002 L⋅hr/kg.

Adminstartion

Administration:

Prepare the intravenous solution with 0.9% NaCl. Do not mix other drugs, as incompatibility may occur. Do not shake; swirl for 15 minutes. Use immediately after the preparation.

Patient Information Leaflet

Patient information leaflet

Generic Name: sacituzumab govitecan

Pronounced: saa-ki-too-zoo-mab goe-vit-e-can

Why do we use sacituzumab govitecan?

sacituzumab govitecan is a topoisomerase inhibitor having antineoplastic properties. It helps treat breast and urothelial cancer.

sacituzumab govitecan

No data available for drug.

DRUG INTERACTION

sacituzumab govitecan

&

sacituzumab govitecan +

Contraindicated

Serious Use Alternative

Monitor Closely

Minor

sacituzumab govitecan

No data available for drug.

DRUG INTERACTION

sacituzumab govitecan

&

sacituzumab govitecan +

Contraindicated

Serious Use Alternative

Monitor Closely

Minor

medtigo

sacituzumab govitecan

Brand Name :

Synonyms :

Class :

Action and Spectrum

Dosing & Uses

Drug Interaction

Adverse Reaction

Black Box Warning

Contraindication / Caution

Pregnancy / Lactation

Pharmacology

Adminstartion

Patient Information Leaflet

CONTACT INFORMATION

ADDRESS

JOIN THE FASTEST GROWING HEALTHCARE COMMUNITY!

Download our APP

CONTACT INFORMATION

ADDRESS

Taking the Pain out of Your Career

DOWNLOAD APP